Research programme: SeV-based gene therapies - ID Pharma

Drug Profile

Research programme: SeV-based gene therapies - ID Pharma

Alternative Names: SeV 10102; SeV 10401; SeV 10501; SeV 20201; SeV 20202; SeV 20301; SeV 20302; SeV2 0401

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DNAVEC Corporation
  • Class Gene therapies; Nucleic acids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Cystic fibrosis; Ischaemic heart disorders

Highest Development Phases

  • No development reported Alzheimer's disease; Brain cancer; Coronavirus infections; Cystic fibrosis; HIV-1 infections; Ischaemic heart disorders; Malignant melanoma; Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Brain-cancer in Japan
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cystic-fibrosis in Japan
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Ischaemic-heart-disorders in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top